Targeting mitochondrial metal dyshomeostasis for the treatment of neurodegeneration

Papers of special note have been highlighted as: • of interest

References

• 1 Moos T, Rosengren Nielsen T, Skjorringe T, Morgan EH. Iron trafficking inside the brain. J. Neurochem. 103(5), 1730–1740 (2007).
  Medline CASGoogle Scholar
• 2 Choi BS, Zheng W. Copper transport to the brain by the blood–brain barrier and blood–CSF barrier. Brain Res. 1248, 14–21 (2009).
  Medline CASGoogle Scholar
• 3 Marger L, Schubert CR, Bertrand D. Zinc: an underappreciated modulatory factor of brain function. Biochem. Pharmacol. 91(4), 426–435 (2014).
  Medline CASGoogle Scholar
• 4 Hare D, Ayton S, Bush A, Lei P. A delicate balance: iron metabolism and diseases of the brain. Front. Aging Neurosci. 5, 34 (2013).
  MedlineGoogle Scholar
• 5 Scheiber IF, Mercer JF, Dringen R. Metabolism and functions of copper in brain. Prog. Neurobiol. 116, 33–57 (2014).
  Medline CASGoogle Scholar
• 6 Vergun O, Dineley KE, Reynold IJ. Ion transport and energy metabolism. In: Handbook of Neurochemistry and Molecular Neurobiology. Lajtha A (Ed.). Springer Science+Business Media, NY, USA, 429–463 (2007).
  Google Scholar
• 7 Waldron KJ, Rutherford JC, Ford D, Robinson NJ. Metalloproteins and metal sensing. Nature 460(7257), 823–830 (2009).
  Medline CASGoogle Scholar
• 8 Calvo SE, Mootha VK. The mitochondrial proteome and human disease. Annu. Rev. Genomics Hum. Genet. 11, 25–44 (2010).
  Medline CASGoogle Scholar
• 9 Stehling O, Wilbrecht C, Lill R. Mitochondrial iron-sulfur protein biogenesis and human disease. Biochimie 100, 61–77 (2014).
  Medline CASGoogle Scholar
• 10 Nilsson R, Schultz IJ, Pierce EL et al. Discovery of genes essential for heme biosynthesis through large-scale gene expression analysis. Cell Metab. 10(2), 119–130 (2009).
  Medline CASGoogle Scholar
• 11 Drose S, Brandt U, Wittig I. Mitochondrial respiratory chain complexes as sources and targets of thiol-based redox-regulation. Biochim. Biophys. Acta 1844(8), 1344–1354 (2014).
  MedlineGoogle Scholar
• 12 Xu W, Barrientos T, Andrews NC. Iron and copper in mitochondrial diseases. Cell Metab. 17(3), 319–328 (2013).
  Medline CASGoogle Scholar
• 13 Wolff NA, Ghio AJ, Garrick LM et al. Evidence for mitochondrial localization of divalent metal transporter 1 (DMT1). FASEB J. (2014).
  MedlineGoogle Scholar
• 14 Palmieri F. Mitochondrial transporters of the SLC25 family and associated diseases: a review. J. Inherit. Metab. Dis. 37(4), 565–575 (2014).
  Medline CASGoogle Scholar
• 15 Paradkar PN, Zumbrennen KB, Paw BH, Ward DM, Kaplan J. Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Mol. Cell Biol. 29(4), 1007–1016 (2009).
  Medline CASGoogle Scholar
• 16 Shaw GC, Cope JJ, Li L et al. Mitoferrin is essential for erythroid iron assimilation. Nature 440(7080), 96–100 (2006).
  Medline CASGoogle Scholar
• 17 Foury F, Roganti T. Deletion of the mitochondrial carrier genes MRS3 and MRS4 suppresses mitochondrial iron accumulation in a yeast frataxin-deficient strain. J. Biol. Chem. 277(27), 24475–24483 (2002).
  Medline CASGoogle Scholar
• 18 Li L, Kaplan J. Characterization of two homologous yeast genes that encode mitochondrial iron transporters. J. Biol. Chem. 272(45), 28485–28493 (1997).
  Medline CASGoogle Scholar
• 19 Froschauer EM, Rietzschel N, Hassler MR et al. The mitochondrial carrier Rim2 co-imports pyrimidine nucleotides and iron. Biochem. J. 455(1), 57–65 (2013).
  Medline CASGoogle Scholar
• 20 Froschauer EM, Schweyen RJ, Wiesenberger G. The yeast mitochondrial carrier proteins Mrs3p/Mrs4p mediate iron transport across the inner mitochondrial membrane. Biochim. Biophys. Acta 1788(5), 1044–1050 (2009).
  Medline CASGoogle Scholar
• 21 Vest KE, Leary SC, Winge DR, Cobine PA. Copper import into the mitochondrial matrix in Saccharomyces cerevisiae is mediated by Pic2, a mitochondrial carrier family protein. J. Biol. Chem. 288(33), 23884–23892 (2013).
  Medline CASGoogle Scholar
• 22 Culotta VC, Yang M, O'Halloran TV. Activation of superoxide dismutases: putting the metal to the pedal. Biochim. Biophys. Acta 1763(7), 747–758 (2006).
  Medline CASGoogle Scholar
• 23 Wong YC, Holzbaur EL. Autophagosome dynamics in neurodegeneration at a glance. J. Cell Sci. 128(7), 1259–1267 (2015).
  Medline CASGoogle Scholar
• 24 Chatterjee S, Sarkar S, Bhattacharya S. Toxic metals and autophagy. Chem. Res. Toxicol. 27(11), 1887–1900 (2014).
  Medline CASGoogle Scholar
• 25 Krishan S, Jansson PJ, Gutierrez E, Lane DJ, Richardson D, Sahni S. Iron metabolism and autophagy: a poorly explored relationship that has important consequences for health and disease. Nagoya J. Med. Sci. 77(1–2), 1–6 (2015).
  Medline CASGoogle Scholar
• 26 Lopes da Fonseca T, Outeiro TF. ATP13A2 and alpha-synuclein: a metal taste in autophagy. Exp. Neurobiol. 23(4), 314–323 (2014).
  MedlineGoogle Scholar
• 27 Finazzi D, Arosio P. Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration. Arch. Toxicol. 88(10), 1787–1802 (2014).
  Medline CASGoogle Scholar
• 28 Levi S, Corsi B, Bosisio M et al. A human mitochondrial ferritin encoded by an intronless gene. J. Biol. Chem. 276(27), 24437–24440 (2001).
  Medline CASGoogle Scholar
• 29 Nie G, Sheftel AD, Kim SF, Ponka P. Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood 105(5), 2161–2167 (2005).
  Medline CASGoogle Scholar
• 30 Ajioka RS, Phillips JD, Kushner JP. Biosynthesis of heme in mammals. Biochim. Biophys. Acta 1763(7), 723–736 (2006).
  Medline CASGoogle Scholar
• 31 Sheftel AD, Stehling O, Pierik AJ et al. Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe/S cluster biosynthesis. Proc. Natl Acad. Sci. USA 107(26), 11775–11780 (2010).
  Medline CASGoogle Scholar
• 32 Shi Y, Ghosh M, Kovtunovych G, Crooks DR, Rouault TA. Both human ferredoxins 1 and 2 and ferredoxin reductase are important for iron-sulfur cluster biogenesis. Biochim. Biophys. Acta 1823(2), 484–492 (2012).
  Medline CASGoogle Scholar
• 33 Tong WH, Rouault TA. Metabolic regulation of citrate and iron by aconitases: role of iron-sulfur cluster biogenesis. Biometals 20(3–4), 549–564 (2007).
  Medline CASGoogle Scholar
• 34 Rae TD, Schmidt PJ, Pufahl RA, Culotta VC, O'Halloran TV. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 284(5415), 805–808 (1999).
  Medline CASGoogle Scholar
• 35 Nevitt T, Ohrvik H, Thiele DJ. Charting the travels of copper in eukaryotes from yeast to mammals. Biochim. Biophys. Acta 1823(9), 1580–1593 (2012).
  Medline CASGoogle Scholar
• 36 Robinson NJ, Winge DR. Copper metallochaperones. Annu. Rev. Biochem. 79, 537–562 (2010).
  Medline CASGoogle Scholar
• 37 Horn D, Barrientos A. Mitochondrial copper metabolism and delivery to cytochrome c oxidase. IUBMB Life 60(7), 421–429 (2008).
  Medline CASGoogle Scholar
• 38 Leary SC, Cobine PA, Nishimura T et al. COX19 mediates the transduction of a mitochondrial redox signal from SCO1 that regulates ATP7A-mediated cellular copper efflux. Mol. Biol. Cell 24(6), 683–691 (2013).
  Medline CASGoogle Scholar
• 39 Kawamata H, Manfredi G. Different regulation of wild-type and mutant Cu, Zn superoxide dismutase localization in mammalian mitochondria. Hum. Mol. Genet. 17(21), 3303–3317 (2008).• Determined that mitochondrial localization of SOD1 is dependent upon oxygen concentration.
  Medline CASGoogle Scholar
• 40 Cobine PA, Ojeda LD, Rigby KM, Winge DR. Yeast contain a non-proteinaceous pool of copper in the mitochondrial matrix. J. Biol. Chem. 279(14), 14447–14455 (2004).
  Medline CASGoogle Scholar
• 41 Cobine PA, Pierrel F, Bestwick ML, Winge DR. Mitochondrial matrix copper complex used in metallation of cytochrome oxidase and superoxide dismutase. J. Biol. Chem. 281(48), 36552–36559 (2006).
  Medline CASGoogle Scholar
• 42 Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid. Redox Signal. 15(6), 1583–1606 (2011).
  Medline CASGoogle Scholar
• 43 Sensi SL, Ton-That D, Sullivan PG et al. Modulation of mitochondrial function by endogenous Zn2+ pools. Proc. Natl Acad. Sci. USA 100(10), 6157–6162 (2003).
  Medline CASGoogle Scholar
• 44 Dittmer PJ, Miranda JG, Gorski JA, Palmer AE. Genetically encoded sensors to elucidate spatial distribution of cellular zinc. J. Biol. Chem. 284(24), 16289–16297 (2009).
  Medline CASGoogle Scholar
• 45 Miranda JG, Weaver AL, Qin Y et al. New alternately colored FRET sensors for simultaneous monitoring of Zn(2)(+) in multiple cellular locations. PLoS One 7(11), e49371 (2012).
  Medline CASGoogle Scholar
• 46 Park JG, Qin Y, Galati DF, Palmer AE. New sensors for quantitative measurement of mitochondrial Zn(2+). ACS Chem. Biol. 7(10), 1636–1640 (2012).
  Medline CASGoogle Scholar
• 47 Eide DJ. Zinc transporters and the cellular trafficking of zinc. Biochim. Biophys. Acta 1763(7), 711–722 (2006).
  Medline CASGoogle Scholar
• 48 Burri L, Vascotto K, Fredersdorf S, Tiedt R, Hall MN, Lithgow T. Zim17, a novel zinc finger protein essential for protein import into mitochondria. J. Biol. Chem. 279(48), 50243–50249 (2004).
  Medline CASGoogle Scholar
• 49 Minczuk M, Kolasinska-Zwierz P, Murphy MP, Papworth MA. Construction and testing of engineered zinc-finger proteins for sequence-specific modification of mtDNA. Nat. Protoc. 5(2), 342–356 (2010).
  Medline CASGoogle Scholar
• 50 Gammage PA, Rorbach J, Vincent AI, Rebar EJ, Minczuk M. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. EMBO Mol. Med. 6(4), 458–466 (2014).
  Medline CASGoogle Scholar
• 51 Harding AE. Clinical features and classification of inherited ataxias. Adv. Neurol. 61, 1–14 (1993).
  Medline CASGoogle Scholar
• 52 Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical features of Friedreich's ataxia: classical and atypical phenotypes. J. Neurochem. 126(Suppl. 1), 103–117 (2013).
  Medline CASGoogle Scholar
• 53 Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J. Neurol. Sci. 303(1–2), 1–12 (2011).
  Medline CASGoogle Scholar
• 54 Koeppen AH, Ramirez RL, Becker AB, Feustel PJ, Mazurkiewicz JE. Friedreich ataxia: failure of GABA-ergic and glycinergic synaptic transmission in the dentate nucleus. J. Neuropathol. Exp. Neurol. 74(2), 166–176 (2015).
  Medline CASGoogle Scholar
• 55 Cossee M, Puccio H, Gansmuller A et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum. Mol. Genet. 9(8), 1219–1226 (2000).
  Medline CASGoogle Scholar
• 56 Schmucker S, Martelli A, Colin F et al. Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. PLoS One 6(1), e16199 (2011).• Demonstrated the role of frataxin in iron–sulfur cluster assembly.
  Medline CASGoogle Scholar
• 57 Rotig A, de Lonlay P, Chretien D et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 17(2), 215–217 (1997).
  Medline CASGoogle Scholar
• 58 Wilson RB, Roof DM. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat. Genet. 16(4), 352–357 (1997).
  Medline CASGoogle Scholar
• 59 Anderson PR, Kirby K, Hilliker AJ, Phillips JP. RNAi-mediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum. Mol. Genet. 14(22), 3397–3405 (2005).
  Medline CASGoogle Scholar
• 60 Long S, Jirku M, Mach J et al. Ancestral roles of eukaryotic frataxin: mitochondrial frataxin function and heterologous expression of hydrogenosomal trichomonas homologues in trypanosomes. Mol. Microbiol. 69(1), 94–109 (2008).
  Medline CASGoogle Scholar
• 61 Martelli A, Wattenhofer-Donze M, Schmucker S, Bouvet S, Reutenauer L, Puccio H. Frataxin is essential for extramitochondrial Fe–S cluster proteins in mammalian tissues. Hum. Mol. Genet. 16(22), 2651–2658 (2007).
  Medline CASGoogle Scholar
• 62 Rouault TA. Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis. Model. Mech. 5(2), 155–164 (2012).
  Medline CASGoogle Scholar
• 63 Sharma AK, Pallesen LJ, Spang RJ, Walden WE. Cytosolic iron-sulfur cluster assembly (CIA) system: factors, mechanism, and relevance to cellular iron regulation. J. Biol. Chem. 285(35), 26745–26751 (2010).
  Medline CASGoogle Scholar
• 64 Huang ML, Becker EM, Whitnall M, Suryo Rahmanto Y, Ponka P, Richardson DR. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc. Natl Acad. Sci. USA 106(38), 16381–16386 (2009).
  MedlineGoogle Scholar
• 65 Whitnall M, Suryo Rahmanto Y, Huang ML et al. Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. Proc. Natl Acad. Sci. USA 109(50), 20590–20595 (2012).
  Medline CASGoogle Scholar
• 66 Huang ML, Lane DJ, Richardson DR. Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease. Antioxid. Redox Signal. 15(12), 3003–3019 (2011).
  Medline CASGoogle Scholar
• 67 Radisky DC, Babcock MC, Kaplan J. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J. Biol. Chem. 274(8), 4497–4499 (1999).
  Medline CASGoogle Scholar
• 68 Velasco-Sanchez D, Aracil A, Montero R et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 10(1), 1–8 (2011).
  Medline CASGoogle Scholar
• 69 Boddaert N, Le Quan Sang KH, Rotig A et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110(1), 401–408 (2007).
  Medline CASGoogle Scholar
• 70 Waldvogel D, van Gelderen P, Hallett M. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann. Neurol. 46(1), 123–125 (1999).
  Medline CASGoogle Scholar
• 71 Bonilha da Silva C, Bergo FP, D'Abreu A, Cendes F, Lopes-Cendes I, Franca MC Jr. Dentate nuclei T2 relaxometry is a reliable neuroimaging marker in Friedreich's ataxia. Eur. J. Neurol. 21(8), 1131–1136 (2014).
  Medline CASGoogle Scholar
• 72 Synofzik M, Godau J, Lindig T, Schols L, Berg D. Transcranial sonography reveals cerebellar, nigral, and forebrain abnormalities in Friedreich's ataxia. Neurodegener. Dis. 8(6), 470–475 (2011).
  MedlineGoogle Scholar
• 73 Solbach K, Kraff O, Minnerop M et al. Cerebellar pathology in Friedreich's ataxia: atrophied dentate nuclei with normal iron content. Neuroimage Clin. 6, 93–99 (2014).
  Medline CASGoogle Scholar
• 74 Bradley JL, Blake JC, Chamberlain S, Thomas PK, Cooper JM, Schapira AH. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Genet. 9(2), 275–282 (2000).
  Medline CASGoogle Scholar
• 75 Koeppen AH, Michael SC, Knutson MD et al. The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins. Acta Neuropathol. 114(2), 163–173 (2007).
  Medline CASGoogle Scholar
• 76 Koeppen AH, Ramirez RL, Yu D et al. Friedreich's ataxia causes redistribution of iron, copper, and zinc in the dentate nucleus. Cerebellum 11(4), 845–860 (2012).
  Medline CASGoogle Scholar
• 77 Koeppen AH, Kuntzsch EC, Bjork ST, Ramirez RL, Mazurkiewicz JE, Feustel PJ. Friedreich ataxia: metal dysmetabolism in dorsal root ganglia. Acta Neuropathol. Commun. 1(1), 26 (2013).
  MedlineGoogle Scholar
• 78 Bayot A, Santos R, Camadro JM, Rustin P. Friedreich's ataxia: the vicious circle hypothesis revisited. BMC Med. 9, 112 (2011).
  Medline CASGoogle Scholar
• 79 Wong A, Yang J, Cavadini P et al. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 8(3), 425–430 (1999).
  Medline CASGoogle Scholar
• 80 Tan G, Chen LS, Lonnerdal B, Gellera C, Taroni FA, Cortopassi GA. Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Hum. Mol. Genet. 10(19), 2099–2107 (2001).
  Medline CASGoogle Scholar
• 81 Calmels N, Schmucker S, Wattenhofer-Donze M et al. The first cellular models based on frataxin missense mutations that reproduce spontaneously the defects associated with Friedreich ataxia. PLoS One 4(7), e6379 (2009).
  MedlineGoogle Scholar
• 82 Puccio H, Simon D, Cossee M et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe–S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 27(2), 181–186 (2001).
  Medline CASGoogle Scholar
• 83 Campanella A, Rovelli E, Santambrogio P, Cozzi A, Taroni F, Levi S. Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia. Hum. Mol. Genet. 18(1), 1–11 (2009).
  Medline CASGoogle Scholar
• 84 Li K, Besse EK, Ha D, Kovtunovych G, Rouault TA. Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum. Mol. Genet. 17(15), 2265–2273 (2008).
  Medline CASGoogle Scholar
• 85 Sohn YS, Breuer W, Munnich A, Cabantchik ZI. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 111(3), 1690–1699 (2008).
  Medline CASGoogle Scholar
• 86 Devos D, Moreau C, Devedjian JC et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid. Redox Signal. 21(2), 195–210 (2014).• First study to demonstrate clinical efficacy of iron chelation for Parkinson's disease.
  Medline CASGoogle Scholar
• 87 Soriano S, Llorens JV, Blanco-Sobero L et al. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia. Gene 521(2), 274–281 (2013).
  Medline CASGoogle Scholar
• 88 Kakhlon O, Manning H, Breuer W et al. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood 112(13), 5219–5227 (2008).
  Medline CASGoogle Scholar
• 89 Li L, Voullaire L, Sandi C et al. Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PloS One 8(2), e55940 (2013).
  Medline CASGoogle Scholar
• 90 Pandolfo M, Arpa J, Delatycki MB et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann. Neurol. 76(4), 509–521 (2014).
  Medline CASGoogle Scholar
• 91 Bradley WG. Overview of motor neuron disease: classification and nomenclature. Clin. Neurosci. 3(6), 323–326 (1995).
  MedlineGoogle Scholar
• 92 Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 124(3), 339–352 (2012).
  Medline CASGoogle Scholar
• 93 Rosen DR, Siddique T, Patterson D et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362(6415), 59–62 (1993).
  Medline CASGoogle Scholar
• 94 Leblond CS, Kaneb HM, Dion PA, Rouleau GA. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp. Neurol. 262(Pt B), 91–101 (2014).
  Medline CASGoogle Scholar
• 95 Marangi G, Traynor BJ. Genetic causes of amyotrophic lateral sclerosis: New genetic analysis methodologies entailing new opportunities and challenges. Brain Res. 1607, 75–93 (2015).
  Medline CASGoogle Scholar
• 96 Sasaki S, Iwata M. Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 66(1), 10–16 (2007).
  MedlineGoogle Scholar
• 97 Kawamata H, Manfredi G. Mitochondrial dysfunction and intracellular calcium dysregulation in ALS. Mech. Ageing Dev. 131(7–8), 517–526 (2010).
  Medline CASGoogle Scholar
• 98 Carri MT, Valle C, Bozzo F, Cozzolino M. Oxidative stress and mitochondrial damage: importance in non-SOD1 ALS. Front. Cell Neurosci. 9, 41 (2015).
  MedlineGoogle Scholar
• 99 Bannwarth S, Ait-El-Mkadem S, Chaussenot A et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 137(Pt 8), 2329–2345 (2014).
  MedlineGoogle Scholar
• 100 Bartolome F, Wu HC, Burchell VS et al. Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels. Neuron 78(1), 57–64 (2013).
  Medline CASGoogle Scholar
• 101 Yin HZ, Nalbandian A, Hsu CI et al. Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice. Cell Death Dis. 3, e374 (2012).
  Medline CASGoogle Scholar
• 102 Magrane J, Cortez C, Gan WB, Manfredi G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum. Mol. Genet. 23(6), 1413–1424 (2013).
  MedlineGoogle Scholar
• 103 Wang W, Li L, Lin WL et al. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum. Mol. Genet. 22(23), 4706–4719 (2013).
  Medline CASGoogle Scholar
• 104 Huang C, Tong J, Bi F et al. Entorhinal cortical neurons are the primary targets of FUS mislocalization and ubiquitin aggregation in FUS transgenic rats. Hum. Mol. Genet. 21(21), 4602–4614 (2012).
  Medline CASGoogle Scholar
• 105 Luo G, Yi J, Ma C et al. Defective mitochondrial dynamics is an early event in skeletal muscle of an amyotrophic lateral sclerosis mouse model. PLoS One 8(12), e82112 (2013).
  MedlineGoogle Scholar
• 106 Vande Velde C, McDonald KK, Boukhedimi Y et al. Misfolded SOD1 associated with motor neuron mitochondria alters mitochondrial shape and distribution prior to clinical onset. PLoS One 6(7), e22031 (2011).
  Medline CASGoogle Scholar
• 107 Vinsant S, Mansfield C, Jimenez-Moreno R et al. Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part II, results and discussion. Brain Behav. 3(4), 431–457 (2013).
  MedlineGoogle Scholar
• 108 Veyrat-Durebex C, Corcia P, Mucha A et al. Iron metabolism disturbance in a French cohort of ALS patients. Biomed. Res. Int. 2014, 485723 (2014).
  MedlineGoogle Scholar
• 109 Yu J, Qi F, Wang N et al. Increased iron level in motor cortex of amyotrophic lateral sclerosis patients: an in vivo MR study. Amyotroph. Lateral Scler. Frontotemporal Degener. 15(5–6), 357–361 (2014).
  Medline CASGoogle Scholar
• 110 Adachi Y, Sato N, Saito Y et al. Usefulness of SWI for the detection of iron in the motor cortex in amyotrophic lateral sclerosis. J. Neuroimaging 25(3), 443–451 (2014).
  MedlineGoogle Scholar
• 111 Ignjatovic A, Stevic Z, Lavrnic S, Dakovic M, Bacic G. Brain iron MRI: a biomarker for amyotrophic lateral sclerosis. J. Magn. Reson. Imaging 38(6), 1472–1479 (2013).
  MedlineGoogle Scholar
• 112 Jeong SY, Rathore KI, Schulz K, Ponka P, Arosio P, David S. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 29(3), 610–619 (2009).
  Medline CASGoogle Scholar
• 113 Dang TN, Lim NK, Grubman A et al. Increased metal content in the TDP-43(A315T) transgenic mouse model of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Front. Aging Neurosci. 6, 15 (2014).
  MedlineGoogle Scholar
• 114 Furukawa Y. Pathological roles of wild-type cu, zn-superoxide dismutase in amyotrophic lateral sclerosis. Neurol. Res. Int. 2012, 323261 (2012).
  MedlineGoogle Scholar
• 115 Vande Velde C, Miller TM, Cashman NR, Cleveland DW. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc. Natl Acad. Sci. USA 105(10), 4022–4027 (2008).
  MedlineGoogle Scholar
• 116 Israelson A, Arbel N, Da Cruz S et al. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron 67(4), 575–587 (2010).
  Medline CASGoogle Scholar
• 117 Li Q, Vande Velde C, Israelson A et al. ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import. Proc. Natl Acad. Sci. USA 107(49), 21146–21151 (2010).
  Medline CASGoogle Scholar
• 118 Pedrini S, Sau D, Guareschi S et al. ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2. Hum. Mol. Genet. 19(15), 2974–2986 (2010).
  Medline CASGoogle Scholar
• 119 Fischer LR, Igoudjil A, Magrane J et al. SOD1 targeted to the mitochondrial intermembrane space prevents motor neuropathy in the Sod1 knockout mouse. Brain 134(Pt 1), 196–209 (2011).
  MedlineGoogle Scholar
• 120 Mattiazzi M, D'Aurelio M, Gajewski CD et al. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 277(33), 29626–29633 (2002).
  Medline CASGoogle Scholar
• 121 Jaarsma D, Rognoni F, van Duijn W, Verspaget HW, Haasdijk ED, Holstege JC. CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropathol. 102(4), 293–305 (2001).
  Medline CASGoogle Scholar
• 122 Igoudjil A, Magrane J, Fischer LR et al. In vivo pathogenic role of mutant SOD1 localized in the mitochondrial intermembrane space. J. Neurosci. 31(44), 15826–15837 (2011).
  Medline CASGoogle Scholar
• 123 Parone PA, Da Cruz S, Han JS et al. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. J. Neurosci. 33(11), 4657–4671 (2013).
  Medline CASGoogle Scholar
• 124 Sturtz LA, Diekert K, Jensen LT, Lill R, Culotta VC. A fraction of yeast Cu, Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria. A physiological role for SOD1 in guarding against mitochondrial oxidative damage. J. Biol. Chem. 276(41), 38084–38089 (2001).
  Medline CASGoogle Scholar
• 125 Field LS, Furukawa Y, O'Halloran TV, Culotta VC. Factors controlling the uptake of yeast copper/zinc superoxide dismutase into mitochondria. J. Biol. Chem. 278(30), 28052–28059 (2003).
  Medline CASGoogle Scholar
• 126 Kawamata H, Manfredi G. Import, maturation, and function of SOD1 and its copper chaperone CCS in the mitochondrial intermembrane space. Antioxid. Redox Signal. 13(9), 1375–1384 (2010).
  Medline CASGoogle Scholar
• 127 Lang L, Kurnik M, Danielsson J, Oliveberg M. Fibrillation precursor of superoxide dismutase 1 revealed by gradual tuning of the protein-folding equilibrium. Proc. Natl Acad. Sci. USA 109(44), 17868–17873 (2012).• Demonstrated that SOD1 aggregation is driven by the unfolded immature monomer.
  Medline CASGoogle Scholar
• 128 Prudencio M, Hart PJ, Borchelt DR, Andersen PM. Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum. Mol. Genet. 18(17), 3217–3226 (2009).
  Medline CASGoogle Scholar
• 129 Acevedo-Arozena A, Kalmar B, Essa S et al. A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. Dis. Model. Mech. 4(5), 686–700 (2011).
  Medline CASGoogle Scholar
• 130 Deitch JS, Alexander GM, Bensinger A, Yang S, Jiang JT, Heiman-Patterson TD. Phenotype of transgenic mice carrying a very low copy number of the mutant human G93A superoxide dismutase-1 gene associated with amyotrophic lateral sclerosis. PLoS One 9(6), e99879 (2014).
  MedlineGoogle Scholar
• 131 Jaarsma D, Haasdijk ED, Grashorn JA et al. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol. Dis. 7(6 Pt B), 623–643 (2000).
  Medline CASGoogle Scholar
• 132 Graffmo KS, Forsberg K, Bergh J et al. Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. Hum. Mol. Genet. 22(1), 51–60 (2013).
  Medline CASGoogle Scholar
• 133 Jonsson PA, Graffmo KS, Andersen PM et al. Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain 129(Pt 2), 451–464 (2006).
  MedlineGoogle Scholar
• 134 Son M, Leary SC, Romain N et al. Isolated cytochrome c oxidase deficiency in G93A SOD1 mice overexpressing CCS protein. J. Biol. Chem. 283(18), 12267–12275 (2008).
  Medline CASGoogle Scholar
• 135 Son M, Puttaparthi K, Kawamata H et al. Overexpression of CCS in G93A-SOD1 mice leads to accelerated neurological deficits with severe mitochondrial pathology. Proc. Natl Acad. Sci. USA 104(14), 6072–6077 (2007).
  Medline CASGoogle Scholar
• 136 Bahadorani S, Mukai ST, Rabie J, Beckman JS, Phillips JP, Hilliker AJ. Expression of zinc-deficient human superoxide dismutase in Drosophila neurons produces a locomotor defect linked to mitochondrial dysfunction. Neurobiol. Aging 34(10), 2322–2330 (2013).
  Medline CASGoogle Scholar
• 137 Hadzhieva M, Kirches E, Wilisch-Neumann A et al. Dysregulation of iron protein expression in the G93A model of amyotrophic lateral sclerosis. Neuroscience 230, 94–101 (2013).
  Medline CASGoogle Scholar
• 138 Wang Q, Zhang X, Chen S et al. Prevention of motor neuron degeneration by novel iron chelators in SOD1(G93A) transgenic mice of amyotrophic lateral sclerosis. Neurodegener. Dis. 8(5), 310–321 (2011).
  Medline CASGoogle Scholar
• 139 Soon CP, Donnelly PS, Turner BJ et al. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J. Biol. Chem. 286(51), 44035–44044 (2011).
  Medline CASGoogle Scholar
• 140 McAllum EJ, Lim NK, Hickey JL et al. Therapeutic effects of Cu(II)(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 14(7–8), 586–590 (2013).
  Medline CASGoogle Scholar
• 141 Roberts BR, Lim NK, McAllum EJ et al. Oral treatment with CuII(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 34(23), 8021–8031 (2014).• CuII(atsm) delays the onset of amyotrophic lateral sclerosis symptoms in mice via delivery of copper to SOD1.
  Medline CASGoogle Scholar
• 142 Beckman J, Williams J, Beilby P et al. Cu-ATSM: an effective treatment for high-expressing G93A-SOD1 mice expressing the human copper chaperone for SOD1 (CCS). Amyotroph. Lateral Scler. Frontotemporal Degener. 15(S1), 45 (2014).
  Google Scholar
• 143 Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 23(11), 3766–3779 (2009).
  Medline CASGoogle Scholar
• 144 Zheng H, Weiner LM, Bar-Am O et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. 13(3), 773–783 (2005).
  Medline CASGoogle Scholar
• 145 Levine T, Hank N, Saperstein D, Bradley W, Cox P. Zinc inhibition of BMAA toxicity. Amyotroph. Lateral Scler. 12(Suppl. 1), 165 (2011).
  Google Scholar
• 146 Riemer J, Kins S. Axonal transport and mitochondrial dysfunction in Alzheimer's disease. Neurodegener. Dis. 12(3), 111–124 (2013).
  Medline CASGoogle Scholar
• 147 Aliev G, Seyidova D, Neal ML et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann. NY Acad. Sci. 977, 45–64 (2002).
  Medline CASGoogle Scholar
• 148 Hirai K, Aliev G, Nunomura A et al. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 21(9), 3017–3023 (2001).
  Medline CASGoogle Scholar
• 149 Kish SJ, Bergeron C, Rajput A et al. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 59(2), 776–779 (1992).
  Medline CASGoogle Scholar
• 150 Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 63(6), 2179–2184 (1994).
  Medline CASGoogle Scholar
• 151 Maurer I, Zierz S, Moller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging 21(3), 455–462 (2000).
  Medline CASGoogle Scholar
• 152 Phillips NR, Simpkins JW, Roby RK. Mitochondrial DNA deletions in Alzheimer's brains: a review. Alzheimers Dement. 10(3), 393–400 (2014).
  MedlineGoogle Scholar
• 153 Hauptmann S, Scherping I, Drose S et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol. Aging 30(10), 1574–1586 (2009).
  Medline CASGoogle Scholar
• 154 Fu YJ, Xiong S, Lovell MA, Lynn BC. Quantitative proteomic analysis of mitochondria in aging PS-1 transgenic mice. Cell Mol. Neurobiol. 29(5), 649–664 (2009).
  Medline CASGoogle Scholar
• 155 Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim. Biophys. Acta 1802(1), 2–10 (2010).
  Medline CASGoogle Scholar
• 156 Lee SH, Kim KR, Ryu SY et al. Impaired short-term plasticity in mossy fiber synapses caused by mitochondrial dysfunction of dentate granule cells is the earliest synaptic deficit in a mouse model of Alzheimer's disease. J. Neurosci. 32(17), 5953–5963 (2012).
  Medline CASGoogle Scholar
• 157 Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 15(9), 1437–1449 (2006).
  Medline CASGoogle Scholar
• 158 Lustbader JW, Cirilli M, Lin C et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304(5669), 448–452 (2004).
  Medline CASGoogle Scholar
• 159 Crouch PJ, Blake R, Duce JA et al. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1–42. J. Neurosci. 25(3), 672–679 (2005).
  Medline CASGoogle Scholar
• 160 Ayton S, Lei P, Bush AI. Biometals and their therapeutic implications in Alzheimer's disease. Neurotherapeutics 12(1), 109–120 (2014).
  Google Scholar
• 161 Bartzokis G, Sultzer D, Mintz J et al. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI. Biol. Psychiatry 35(7), 480–487 (1994).
  Medline CASGoogle Scholar
• 162 Honda K, Smith MA, Zhu X et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J. Biol. Chem. 280(22), 20978–20986 (2005).
  Medline CASGoogle Scholar
• 163 Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl Acad. Sci. USA 94(18), 9866–9868 (1997).
  Medline CASGoogle Scholar
• 164 Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM. Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog. Neurobiol. 94(3), 296–306 (2011).
  Medline CASGoogle Scholar
• 165 Rembach A, Hare DJ, Lind M et al. Decreased copper in Alzheimer's disease brain is predominantly in the soluble extractable fraction. Int. J. Alzheimers Dis. 2013, 623241 (2013).
  MedlineGoogle Scholar
• 166 Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. J. Struct. Biol. 155(1), 30–37 (2006).
  Medline CASGoogle Scholar
• 167 Ayton S, Lei P, Duce JA et al. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann. Neurol. 73(4), 554–559 (2013).
  Medline CASGoogle Scholar
• 168 Wong BX, Tsatsanis A, Lim LQ, Adlard PA, Bush AI, Duce JA. beta-amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS One 9(12), e114174 (2014).
  MedlineGoogle Scholar
• 169 Duce JA, Tsatsanis A, Cater MA et al. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142(6), 857–867 (2010).
  Medline CASGoogle Scholar
• 170 Lei P, Ayton S, Finkelstein DI et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18(2), 291–295 (2012).
  Medline CASGoogle Scholar
• 171 Wu WS, Zhao YS, Shi ZH et al. Mitochondrial ferritin attenuates beta-amyloid-induced neurotoxicity: reduction in oxidative damage through the Erk/P38 mitogen-activated protein kinase pathways. Antioxid. Redox Signal. 18(2), 158–169 (2013).
  Medline CASGoogle Scholar
• 172 Adlard PA, Cherny RA, Finkelstein DI et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59(1), 43–55 (2008).
  Medline CASGoogle Scholar
• 173 Cherny RA, Atwood CS, Xilinas ME et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30(3), 665–676 (2001).
  Medline CASGoogle Scholar
• 174 White AR, Du T, Laughton KM et al. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281(26), 17670–17680 (2006).• Discovered metal ionophore mechanism of action for clioquinol.
  Medline CASGoogle Scholar
• 175 Crouch PJ, Savva MS, Hung LW et al. The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity. J. Neurochem. 119(1), 220–230 (2011).
  Medline CASGoogle Scholar
• 176 Lei P, Ayton S, Appukuttan AT et al. Clioquinol rescues parkinsonism and dementia phenotypes of the tau knockout mouse. Neurobiol. Dis. (In Press) (2015).
  MedlineGoogle Scholar
• 177 Malm TM, Iivonen H, Goldsteins G et al. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J. Neurosci. 27(14), 3712–3721 (2007).
  Medline CASGoogle Scholar
• 178 Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Weinreb O. The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid. Redox Signal. 17(6), 860–877 (2012).
  Medline CASGoogle Scholar
• 179 Kamalinia G, Khodagholi F, Atyabi F et al. Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies. Mol. Pharm. 10(12), 4418–4431 (2013).
  Medline CASGoogle Scholar
• 180 Crouch PJ, Hung LW, Adlard PA et al. Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc. Natl Acad. Sci. USA 106(2), 381–386 (2009).
  Medline CASGoogle Scholar
• 181 Crapper McLachlan DR, Dalton AJ, Kruck TP et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337(8753), 1304–1308 (1991).
  Medline CASGoogle Scholar
• 182 Ritchie CW, Bush AI, Mackinnon A et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60(12), 1685–1691 (2003).
  MedlineGoogle Scholar
• 183 Lannfelt L, Blennow K, Zetterberg H et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a Phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7(9), 779–786 (2008).
  Medline CASGoogle Scholar
• 184 Faux NG, Ritchie CW, Gunn A et al. PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J. Alzheimers Dis. 20(2), 509–516 (2010).
  Medline CASGoogle Scholar
• 185 Bano D, Zanetti F, Mende Y, Nicotera P. Neurodegenerative processes in Huntington's disease. Cell Death Dis. 2, e228 (2011).
  Medline CASGoogle Scholar
• 186 Duan W, Jiang M, Jin J. Metabolism in HD: still a relevant mechanism? Mov. Disord. 29(11), 1366–1374 (2014).
  MedlineGoogle Scholar
• 187 Muller M, Leavitt BR. Iron dysregulation in Huntington's disease. J. Neurochem. 130(3), 328–350 (2014).
  Medline CASGoogle Scholar
• 188 Dexter DT, Carayon A, Javoy-Agid F et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(Pt 4), 1953–1975 (1991).
  MedlineGoogle Scholar
• 189 Loeffler DA, LeWitt PA, Juneau PL et al. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res. 738(2), 265–274 (1996).
  Medline CASGoogle Scholar
• 190 Rosas HD, Chen YI, Doros G et al. Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch. Neurol. 69(7), 887–893 (2012).
  MedlineGoogle Scholar
• 191 Fox JH, Kama JA, Lieberman G et al. Mechanisms of copper ion mediated Huntington's disease progression. PLoS One 2(3), e334 (2007).
  MedlineGoogle Scholar
• 192 Chen J, Marks E, Lai B et al. Iron accumulates in Huntington's disease neurons: protection by deferoxamine. PLoS One 8(10), e77023 (2013).
  Medline CASGoogle Scholar
• 193 Perez P, Flores A, Santamaria A, Rios C, Galvan-Arzate S. Changes in transition metal contents in rat brain regions after in vivo quinolinate intrastriatal administration. Arch. Med. Res. 27(4), 449–452 (1996).
  Medline CASGoogle Scholar
• 194 Martinez-Lazcano JC, Montes S, Sanchez-Mendoza MA et al. Sub-chronic copper pretreatment reduces oxidative damage in an experimental Huntington's disease model. Biol. Trace Elem. Res. 162(1–3), 211–218 (2014).
  Medline CASGoogle Scholar
• 195 Hodges A, Strand AD, Aragaki AK et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 15(6), 965–977 (2006).
  Medline CASGoogle Scholar
• 196 Hilditch-Maguire P, Trettel F, Passani LA, Auerbach A, Persichetti F, MacDonald ME. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet. 9(19), 2789–2797 (2000).
  Medline CASGoogle Scholar
• 197 Sheline CT, Zhu J, Zhang W, Shi C, Cai AL. Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo. Neurodegener. Dis. 11(1), 49–58 (2013).
  MedlineGoogle Scholar
• 198 Cherny RA, Ayton S, Finkelstein DI, Bush AI, McColl G, Massa SM. PBT2 reduces toxicity in a C. elegans model of polyq aggregation and extends lifespan, reduces striatal atrophy and improves motor performance in the R6/2 mouse model of Huntington's disease. J. Huntingtons Dis. 1(2), 211–219 (2012).
  MedlineGoogle Scholar
• 199 Investigators HSGRH. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 14(1), 39–47 (2015).
  MedlineGoogle Scholar
• 200 Litvan I, Chesselet M-F, Gasser T et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J. Neuropathol. Exp. Neurol. 66(5), 329–336 (2007).
  Medline CASGoogle Scholar
• 201 Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 388(6645), 839–840 (1997).
  Medline CASGoogle Scholar
• 202 Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2(7), 492–501 (2001).
  Medline CASGoogle Scholar
• 203 Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1(8649), 1269 (1989).
  Medline CASGoogle Scholar
• 204 Mizuno Y, Ohta S, Tanaka M et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163(3), 1450–1455 (1989).
  Medline CASGoogle Scholar
• 205 Tanner CM, Kamel F, Ross GW et al. Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 119(6), 866–872 (2011).
  Medline CASGoogle Scholar
• 206 Ayton S, Lei P. Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. Biomed. Res. Int. 2014, 581256 (2014).
  MedlineGoogle Scholar
• 207 Popescu BF, George MJ, Bergmann U et al. Mapping metals in Parkinson's and normal brain using rapid-scanning x-ray fluorescence. Phys. Med. Biol. 54(3), 651–663 (2009).
  MedlineGoogle Scholar
• 208 Davies KM, Bohic S, Carmona A et al. Copper pathology in vulnerable brain regions in Parkinson's disease. Neurobiol. Aging 35(4), 858–866 (2014).
  Medline CASGoogle Scholar
• 209 Mochizuki H, Imai H, Endo K et al. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci. Lett. 168(1–2), 251–253 (1994).
  Medline CASGoogle Scholar
• 210 Temlett JA, Landsberg JP, Watt F, Grime GW. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J. Neurochem. 62(1), 134–146 (1994).
  Medline CASGoogle Scholar
• 211 Fleming RE, Migas MC, Holden CC et al. Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc. Natl Acad. Sci. USA 97(5), 2214–2219 (2000).
  Medline CASGoogle Scholar
• 212 Lee DW, Rajagopalan S, Siddiq A et al. Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J. Biol. Chem. 284(42), 29065–29076 (2009).
  Medline CASGoogle Scholar
• 213 Mastroberardino PG, Hoffman EK, Horowitz MP et al. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol. Dis. 34(3), 417–431 (2009).
  Medline CASGoogle Scholar
• 214 Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660(1), 8–18 (1994).
  Medline CASGoogle Scholar
• 215 Rios C, Alvarez-Vega R, Rojas P. Depletion of copper and manganese in brain after MPTP treatment of mice. Pharmacol. Toxicol. 76(6), 348–352 (1995).
  Medline CASGoogle Scholar
• 216 Schipper HM, Vininsky R, Brull R, Small L, Brawer JR. Astrocyte mitochondria: a substrate for iron deposition in the aging rat substantia nigra. Exp. Neurol. 152(2), 188–196 (1998).
  Medline CASGoogle Scholar
• 217 Sian J, Dexter DT, Lees AJ et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36(3), 348–355 (1994).
  Medline CASGoogle Scholar
• 218 Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 104(6–7), 661–677 (1997).
  Medline CASGoogle Scholar
• 219 Martin HL, Teismann P. Glutathione – a review on its role and significance in Parkinson's disease. FASEB J. 23(10), 3263–3272 (2009).
  Medline CASGoogle Scholar
• 220 Lee DW, Kaur D, Chinta SJ, Rajagopalan S, Andersen JK. A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease. Antioxid. Redox Signal. 11(9), 2083–2094 (2009).
  Medline CASGoogle Scholar
• 221 Park JS, Koentjoro B, Veivers D, Mackay-Sim A, Sue CM. Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. Hum. Mol. Genet. 23(11), 2802–2815 (2014).
  Medline CASGoogle Scholar
• 222 Kaur D, Yantiri F, Rajagopalan S et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37(6), 899–909 (2003).
  Medline CASGoogle Scholar
• 223 Shi ZH, Nie G, Duan XL et al. Neuroprotective mechanism of mitochondrial ferritin on 6-hydroxydopamine-induced dopaminergic cell damage: implication for neuroprotection in Parkinson's disease. Antioxid. Redox Signal. 13(6), 783–796 (2010).
  Medline CASGoogle Scholar
• 224 Santiago M, Matarredona ER, Granero L, Cano J, Machado A. Neuroprotective effect of the iron chelator desferrioxamine against MPP+ toxicity on striatal dopaminergic terminals. J. Neurochem. 68(2), 732–738 (1997).
  Medline CASGoogle Scholar
• 225 Ben-Shachar D, Eshel G, Finberg JP, Youdim MB. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56(4), 1441–1444 (1991).
  Medline CASGoogle Scholar
• 226 Ben-Shachar D, Eshel G, Riederer P, Youdim MB. Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Ann. Neurol. 32(Suppl.), S105–110 (1992).
  Medline CASGoogle Scholar
• 227 Lan J, Jiang DH. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm. 104(4–5), 469–481 (1997).
  Medline CASGoogle Scholar
• 228 Zhang Z, Zhang K, Du X, Li Y. Neuroprotection of desferrioxamine in lipopolysaccharide-induced nigrostriatal dopamine neuron degeneration. Mol. Med. Report. 5(2), 562–566 (2012).
  Medline CASGoogle Scholar
• 229 Dexter DT, Statton SA, Whitmore C et al. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J. Neural Transm. 118(2), 223–231 (2011).
  Medline CASGoogle Scholar
• 230 Liddell JR, Obando D, Liu J et al. Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease. Free. Radic. Biol. Med. 60, 147–156 (2013).
  Medline CASGoogle Scholar
• 231 Alcaraz-Zubeldia M, Rojas P, Boll C, Rios C. Neuroprotective effect of acute and chronic administration of copper (II) sulfate against MPP+ neurotoxicity in mice. Neurochem. Res. 26(1), 59–64 (2001).
  Medline CASGoogle Scholar
• 232 Youdim MB, Grunblatt E, Mandel S. The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice. J. Neural Transm. 114(2), 205–209 (2007).
  Medline CASGoogle Scholar
• 233 Hung LW, Villemagne VL, Cheng L et al. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. J. Exp. Med. 209(4), 837–854 (2012).
  Medline CASGoogle Scholar
• 234 Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46(2), 254–263 (2004).
  MedlineGoogle Scholar
• 235 Gal S, Zheng H, Fridkin M, Youdim MBH. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 95(1), 79–88 (2005).
  Medline CASGoogle Scholar
• 236 Gal S, Zheng H, Fridkin M, Youdim MB. Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox. Res. 17(1), 15–27 (2010).
  Medline CASGoogle Scholar
• 237 Mechlovich D, Amit T, Bar-Am O, Mandel S, Youdim MB, Weinreb O. The novel multi-target iron chelator, M30 modulates HIF-1alpha-related glycolytic genes and insulin signaling pathway in the frontal cortex of APP/PS1 Alzheimer's disease mice. Curr. Alzheimer Res. 11(2), 119–127 (2014).
  Medline CASGoogle Scholar